148 Rita Moretti, Paola Torre and Rodolfo M. Antonello

[19] Lipton SA, Kim WK, Choi YB, Kumar S, D’Emilia DM, Rayudu PV, Arnelle DR,

Stamler JS. Neurotoxicity associated with dual actions of homocysteine at the Nmethyl-D-aspartate receptor. Proc. Natl. Acad. Sci. 1997; 94: 5923-5928.

[20] Perry IJ, Refsum H, Morris RW, Ebrahim SB, Ueland PM, Shaper AG. Lancet, 1995;

346: 1395-1398.

[21] Weir DG, Scott JM. Brain function in the elderly: role of vitamin B12 and folate. Br.

Med. Bull. 1999; 55(3): 669-682.

[22] Martin DC. B12 and folate deficiency dementia. Clin. Geriatr. Med. 1988; 4(4): 841-

852.

[23] Moretti R, Torre P, Antonello RM, Cazzato G. Deficit cognitivi reversibili da carenza

di vitamina B12: un confronto neuropsicologico con AD. In: E.Aguglia : Demenze,CIC

edizioni Internazionali, Roma, 2001, Pp.42-45.

[24] Moretti R, Torre P, Antonello RM, Cazzato G. Is isolated vitamin B12 deficiency a

sufficient causative factor of dementia? Eur. J. Neurol., 2001; 8: 87-88.

[25] Moretti R, Torre P, Antonello RM., Cazzato G, Bava A Vitamin B12 – defect: what

does it mean to cognition?, European Journal of Neurology, 2001; 8: 731.

[26] Tucker K., Mahnken B., Wilson P., Jacques P., Selhub J. Folic and fortification of the

food supply:potential benefits and risks for the elderly population. JAMA. 1996, 18/276

(23): 1879-1885.

[27] Ubbink J. Should all elderly people receive folate supplement? Drugs Aging. 1998; 13

[6]: 415-420.

[28] Mollin D.L., Ross C.I.M. Serum vitamin B12 concentrations of patients with

megaloblastic anaemia after treatment with vitamin B12, folic acid or folinic acid.

British Medical Journal. 1953 ii; 640-645.

[29] Dickinson CJ. No reliable evidence that folate is harmful in B12 deficiency. BMJ,

1995; 311: 257.

[30] Samuels MA. Neurocardiology and neuropulmonary. American Academy of

Neurology, 2003; Honolulu: 3FC.001: 1-96.

[31] Larner A.J., Janssen J., Cipollotti L., Rossor M. Cognitive profile in dementia

associated with vitamin B12 deficiency due to pernicious anaemia. Journal of

Neurology, 246: 1999; 317-319.

[32] Larner AJ, Rakshi JS. Vitmain B12 deficiency and dementia. Eur. J. Neurol., 2001, 8:

765-769.

[33] Moretti R, Torre P, Antonello RM, Cazzato G, Bava A, Scapicchio PL. Vitamin B12

and folate depletion: a sufficient causative factor of cognitive impairment? 2003, under

consideration.

[34] Nilsson Ehle H. Age-related changes in cobalamin handling, Implications for therapy.

Drugs Aging. 1998; 12 (4): 277-292.

[35] Hector M, Burton JR. What are the psychiatric manifestations of vitamin B12

deficiency? J.Am. Geriatr. Soc. 1988; 36 (12): 1105-1112.

[36] Bernard MA, Nakonezny PA, Kashner TM. The effect of vitamin B12 deficiency on

older veterans and its relationship to health. J. Am. Geriatr. Soc. 1998; 46: 1199-1206.

Vitamin B12, Folate Depletion and Homcysteine… 149

[37] Bell IR, Edman JS, Marby DW, et al. Vitamin B12 and folate status in acute

psychogeriatric inpatients: affective and cognitive characteristics of a vitamin

nondeficient population. Biol. Psychiatry. 1990; 27: 125-137.

[38] Teunisse S., Bollen A., Van Gool W., Walstra G. Dementia and subnormal levels of

vitamin B12: effects of replacement therapy on dementia. Journal of Neurology, 1996,

243 (7): 522-529.

[39] Basun H, Fratiglioni L, Winblad B. Cobalamin levels are not reduced in Alzheimer’s

disease: results from a population-based study. J. Am. Geriatr. Soc., 1994; 42: 132-136.

[40] Joosten E., Lesaffre E., Riezler R. et al.. Is metabolic evidence for vitamin B 12 and

folate deficiency more frequent in elderly patients with Alzheimer Disease? J.

Gerontol. Med. Sci. 1997; 52A: M76-M79.

[41] Whyte EM, Mulsant BH, Butters MA, Qayyum M, Towers A, Sweet RA, Klunk W,

Wisniewski S, DeKosky ST. Cognitive and behavioural correlates of low vitamin B12

levels in elderly patients with progressive dementia. Am. J. Geriatr. Psychiatry. 2002;

10 (3): 321-327.

[42] Healton EB, Savage DG, Brust JC et al. Neurologic aspects of cobalamin deficiency.

Medicine. (Baltimore), 1991; 70: 229-245.

[43] Martin DC, Francis J, Protech J. et al. Time dependency of cognitive recovery with

cobalamin replacement: report of a pilot study. J. Am. Geriatr. Soc. 1992; 40: 168-172.

[44] Meadows ME, Kaplan RF, Bromfield EB. Cognitive recovery with vitamin B12

therapy: a longitudinal neuropsychological assessment. Neurology. 1994; 44: 1764-

1765.

[45] Eastley R, Wilcock GK, Bucks RS. Vitamin B12 deficiency in dementia and cognitive

impairment: the effects of treatment on neuropsychological function. Int. J. Geriatr.

Psychiatry. 2000; 15 (3): 226-233.

[46] Bell I.R., Edman J., Marby D. et al. Vitamin B12 and folate status in acute

psychogeriatric inpatients: affective and cognitive characteristics of a vitamin

nondeficient population. Biological Psychiatry. 1990, 27: 125-137.

[47] De la Fourniere F., Ferry M., Crockaert X. et al. Deficience en vitamine B12 et etat

dementiel: etude epidemiologique multicentrique et therapeutique. Essai preliminare.

Semantique Hop. 1997; 73 (5-6): 133-140.

[48] Riggs KM, Spiro A III, Tucker K, Rush D. Relations of vitamin B12, vitamin B6,

folate, and homocysteine to cognitive performance in the Normative Aging Study. Am.

J. Clin. Nutr. 1996; 63: 306-314.

[49] Hultberg B, Isaksson A, Nilsson K, Gustafson L. Markers for the functional availability

of cobalamin/folate and their association with neuropsychiatric symptoms in the

elderly. Int. J. Geriatr. Pscyhiatry. 2001; 16 (9): 873-878.

[50] Robins Wahlin RB, Wahlin A, Winblad B, Backman L. The influence of serum vitamin

B12 and folate status on cognitive functioning in very old age. Biol. Psychol. 2001; 56

(3): 247-265.

[51] Fioravanti M., Ferrario F., Massaio M., Cappa G., Rivolta G., Grossi E., Buckley A.

Low folate levels in the cognitive decline of elderly patients and the efficacy of folate

as a treatment for improving memory deficit. Archives of Gerontology and Geriatrics,

1997, 26/1: 1-13.

150 Rita Moretti, Paola Torre and Rodolfo M. Antonello

[52] Hassing L, Wahlin A, Winblad B, Backman L. Further evidence on the effects of

vitamin B12 and folate levels on episodic memory functioning: a population based

study of healthy very old adults. Biol. Psychiatry. 1999; 45 (11): 1472-1480.

[53] Eussen SJ, Ferry M, Hininger I, Haller J, Matthys C, Dirren H. Five years changes in

mental health and associations with vitamin B12 with vitamin B12/folate status of

elderly Europeans. J. Nutr. Health Aging. 2002; 6(1): 43-50.

[54] Nilsson K, Gustafson L, Hultberg B. Improvement of cognitive functions after

cobalamin/folate supplementation in elderly patients with dementia and elevated

plasma homocysteine. Int. J. Geriatr. Psychiatry. 2001; 16 (6): 609-614.

[55] Bryan J, Calvaresi E, Hughes D. Short-term folate, vitamin B12 or vitamin B6

supplementation slightly affects memory performance but not mood in women of

various ages. J. Nutr. 2002; 132 (6): 1345-1356.

[56] Reynolds EH. Folic acid, ageing, depression and dementia. British Medical Journ.

2002, 324: 1512-1515.

[57] Mattson MP, Shea TB. Folate and homocysteine metabolism in neural plasticity and

neurodegenerative disorders. Trends Neurosci. 2003; 26(3): 137-146.

[58] Miller JW. Homocysteine, folate deficiency, and Parkinson’s Disease. Nutr. Rev. 2002;

60 (12): 410-413.

[59] Bottiglieri T, Laundy M, Crellin R, Toone BK, Carney MWP, Reynolds EH.

Homocysteine, folate, methylation, and monoamine metabolism in depression. J.

Neurol. Neurosurg. Psychiatry. 2000; 69: 228-232.

[60] Reynolds EH. Benefits and risks of folic acid to the nervous system. Journ. of Neurol.

Neurosurg. Psychiatry. 2002; 72: 567-571.

[61] Bottiglieri T, Crellin R, Reynolds EH. Folate and neuropsychiatry. In: Bailey LB, ed.

Folate in health and disease. NewYork: Marcel Dekker, 1995:435-462.

[62] Reynolds EH. Mental effects of anticonvulsants, and folic acid metabolism. Brain.

1968; 91: 197-214.

[63] Hommes OR, Hollinger JL, Jansen MIT, Schoofs M, Vanderweil T, Kox JCN.

Convulsant properties arrolate compounds: some considerations and speculations. In:

Botez MI, ReynoIds EH, eds. Folic acid in neurology, psychiatry and internal

medicine. New York: Raven, 1979.

[64] Botez MI, Reynolds EH, eds. Folic acid in neurology, psychiatry and internal

medicine. New York: Raven, 1979.

[65] Bottiglieri T, Reynolds EH, Laundy M. Folate in CSF and age. J. Neurol. Neurosurg.

Psychiatry. 2000; 69: 562.

[66] Maxwell CJ, Hogan DB, Ebly EM. Serum folate levels and subsequent adverse

cerebrovascular outcomes in elderly persons. Dement. Geriatr. Cogn. Disord. 2002; 13:

225-234.

[67] Boushey CJ, Beresford SA, Ameno GS, Matulsky AG. A quantitative assessment of

plasma homocysteine as a risk factor far vascular disease. Probable benefits of

increasing folic acid intakes. JAMA. 1995; 274: 1049-1057.

[68] Eikelboom JW, Lonn E, Genest l, Hankey G, Yusuf S.Homocysteine and

cardiovascular disease: A critical review of the epidemiologic evidence. Ann. Intern.

Med. 1999;131:363-375.

Vitamin B12, Folate Depletion and Homcysteine… 151

[69] Kark LD, Selhub L, Adler B, Gofin J, Abramson LH, Friedman G, Rosenberg IH:

Nonfasting plasma total homocysteine level and mortality in middle-aged and elderly

men and women in Jerusalem. Ann. Intern. Med. 1999;131:321-330.

[70] Bostom AG, Silbershatz H, RosenbergIH, Selhub J, D'Agostino RB, WolfPA,

JacquesPF, Wilson PWF Nonfasting plasma total homacysteine levels and all-cause

and cardiovascular disease mortality in elderly Framingham men and women. Arch.

Intern. Med. 1999;159:1077-1080.

[71] Bostom AG, RosenbergIH, Silbershatz H, Jacques PF, Selhub l, D'Agostino RB,

Wilson PWF, Wolf PA. Nonfasting plasma total homocysteine levels and stroke

incidence in elderly persons: The Framingham study. Ann. Inten. Med. 1999;131:352-

355.

[72] Reynolds EH, Rothfeld P, Pincus L. Neurological disease associated with folate

deficiency. BMJ. 1973; ii: 398-400.

[73] Runcie J. Folate deficiency in the elderly. In: Botez MI, Reynolds EH, eds. Folic acid

in neurology, psychiatry and internal medicine. New York: Raven, 1979:493-499.

[74] Sneath P, Chanarin I, Hodkinson HM, McPherson CK, Reynolds EH. Status in a

geriatric population and its relation to dementia. Age Ageing. 1973; 2: 177-182.

[75] Wang H-X, Wahlin A, Basun H, Fastbom J, Winblad B, Fratiglioni L. Vitamin B 12

and folate in relation to the development of Alzheimer's disease. Neurology. 2001; 56:

1188-1194.

[76] Goodwin JS, Goodwin JM, Garry PL. Association between nutritional status and

cognitive functioning in a healthy elderly population. JAMA. 1983; 249: 2917-2921.

[77] Seshadri S, Beiser A, Selhub J, Jacques PF, Rosenber IH, D'Agostino RB, et al. Plasma

homocysteine as a risk factor for dementia and Alzheimer's disease. N. Engl. J. Med.

2002; 346: 476 –483

[78] Botez MI, Fontaine F, Botez T, Bachevalier I. Folate-responsive neurological and

mental disorders: report of 16 cases. Eur. Neurol. 1977; 16: 230-246.

[79] Snowdon DA, Tully CL, Smith CH, Perez Riley K, Markesbery WR. Serum folate and

the severity of atrophy of the neocortex in Alzheimer Disease: findings from the Nun

Study. Am. J. Clin. Nutr. 2000; 71 (4): 993-998.

[80] Wahlin TBR, Wahlin A, WinbladB, Backman L. The influence of serum vitamin B12

and folate status on cognitive functioning in very old age. Biol. Psychol. 2001; 56: 247-

265.

[81] Clarke R, Smith AD, Jobst KA, Refsum H, SuttonL, Ueland PM, et al. Folate, vitamin

B12, and serum total homocysteine levels in confirmed Alzheimer disease. Arch.

Neurol. 1998; 55: 1449-1455.

[82] Ebly EM, Schaefer JP, Campbell NRC., et al. Folate status, vascular disease and

cognition in elderly Canadians. Age Ageing. 1998; 27: 485-491.

[83] Brocker P, Lebel C, Maurin H, Lods JC. Carences en folates chez les sujets ages:

interet de leur correction dans le traitement des troubles du comportement. Semaine des

Hopitaux de Paris. 1986; 62: 2135-2139.

[84] Hultberg B, Isaksson A, Nilsson K, Gustafson L. Homocysteine and methylmalonic

acid as a markers of cobalamin/folate status. The association to neuropsychiatric

symptoms in the elderly is explored. Lakartidningen. 2000; 97 (38): 4131-4136.

152 Rita Moretti, Paola Torre and Rodolfo M. Antonello

[85] Diaz-Arrastia R. Homocysteine and neurologic disease. Arch. Neurol. 2000; 57 (10):

1422-1427.

[86] Duthie SJ, Whalley LJ, Collins AR, Leaper S, Berger K, Deary IJ. Homocysteine, B

vitamin status, and cognitive function in the elderly. Am. J.Clin. Nutrit. 2002, 75 (5):

908-913.

[87] Clarke R, Smith AD, Jobst KA, Sutton L, Ueland PM. Folate, vitamin B12 and serum

total homocysteine levels in confirmed Alzheimer disease. Arch. Neurol. 1998; 55(11):

1449-1455.

[88] Kruman II, Culmsee C, Chan Sl, Kruman Y, Guo Z, Penix L., et al. Homocysteine

elicits a DNA damage response in neurons that promotes apoptosis and hypersensitivity

to excitotoxicity. J. Neurosci. 2000; 20: 6920-6926.

[89] Den Heijer T, Vermeer SE, Clarke R, Oudkerk M, Koudstaal PJ, Hofman A, Bretler

MMB. Homocysteine and brain atrophy on MRI of non-demented elderly. Brain. 2002;

126: 170-175.

[90] Leblhuber F, Walli J, Artner-DworzakE, Vrecko K, Widner B, Reibnegger G, Fuchs D.

Hyperhomocysteinemia in dementia. J. Neural. transmission. 2000; 107 (12): 1469-

1474.

[91] Joosten E. Homocysteine, vascular dementia, and Alzheimer’s Disease. Clin. Chem.

Lab. Med. 2001; 39 (8): 717-720.

In: Vitamin B: New Research ISBN: 978-1-60021-782-1

Editor: C. M. Elliot, pp. 153-174 © 2008 Nova Science Publishers, Inc.

Chapter IX

VITAMIN B6 AS LIVER-TARGETING

GROUP IN DRUG DELIVERY

Guo-Ping Yan∗ , Xiao-Yan Wang and Li-Li Mei

School of Material Science and Engineering, Wuhan Instituite of Technology,

Wuhan 430073, P. R. China.

ABSTRACT

Vitamin B6 includes a series of compounds containing the pyridoxal structure, such

as pyridoxol, pyridoxamine, pyridoxaldehyde and their derivatives. The pyridoxal

structure，the catalytically active form of vitamin B6, possesses specific hepatocyte

uptake by the pyridoxine transporter at the sinusoidal pole because the pyridoxine

transporters that exist in hepatocytes can selectively recognize and bind to the pyridoxal

structure, and transport it into the cells via a member transport system. Thus pyridoxine

can be adopted as a liver-targeting group and be incorporated into the low molecular

weight compounds and macromolecules for the use as magnetic resonance imaging

(MRI) contrast agents and anticancer conjugates. The research progress of liver-targeting

drug delivery system is discussed briefly. Previous researches have demonstrated that the

incorporation of pyridoxine into these molecules can increase their uptake by the liver,

and that these molecules containing pyridoxine groups exhibit liver-targeting properties.

Keywords: vitamin B6, liver-targeting, drug delivery, magnetic resonance imaging (MRI)

∗

 Correspondence concerning this article should be addressed to: Guo-Ping Yan, School of Material Science and

Engineering, Wuhan Instituite of Technology, Wuhan 430073, P. R. China. E-mail address:

guopyan@hotmail.com.

154 Guo-Ping Yan, Xiao-Yan Wang, Li-Li Mei

INTRODUCTION

Vitamin B6, also known as pyridoxine, is water-soluble and is required for both mental

and physical health. Vitamin B6 includes a series of compounds containing the pyridoxal

structure, such as pyridoxol, pyridoxamine, pyridoxaldehyde and their derivatives.

The liver has both a unique blood supply (arterial, venous and portal-venous) and

specific cells that are capable of transporting/accumulating bulk amounts of both endo- and

exobiotic substances [1-3]. The pyridoxine transporters that exist in hepatocytes at the

sinusoidal pole can selectively recognize and bind to the pyridoxal structure, and transport it

into the cells via a member transport system. The pyridoxal structure, the catalytically active

form of vitamin B6, possesses specific hepatocyte uptake by the pyridoxine transporter. Thus

pyridoxine can be adopted as a liver-targeting group and be incorporated into the low

molecular weight compounds and macromolecules for the use as magnetic resonance imaging

(MRI) contrast agents and anticancer conjugates [4-7]. The research progress of livertargeting drug delivery system is discussed briefly. Previous researches have demonstrated

that the incorporation of pyridoxine into these molecules can increase their uptake by the

liver, and that these molecules containing pyridoxine groups exhibited liver-targeting

properties [8-19].

LIVER-TARGETING MRI CONTRAST AGENTS

Over the last three decades, nuclear magnetic resonance (NMR) has been perhaps the

most powerful method for the non-invasive investigation of human anatomy, physiology and

pathophysiology. Developed in 1973 by Paul Lauterbur [20], magnetic resonance imaging

(MRI) has become widely used as the diagnosis and treatment of human diseases in hospitals

around the world, since it received FDA approval for clinical use in 1985. It is a non-invasive

clinical imaging modality, which relies on the detection of NMR signals emitted by hydrogen

protons in the body placed in a magnetic field. In 2003, Paul C. Lauterbur and Sir Peter

Mansfield won the Nobel Prize in physiology and medicine for their discoveries concerning

MRI because it can be widely used for the diagnosis and treatment of human diseases, such

as necrotic tissue, infarcted artery and malignant disease [21,22].

One important way to improve the contrast in MRI is to introduce contrast agents. MRI

contrast agents are a unique class of pharmaceuticals that enhance the image contrast between

normal and diseased tissue and indicate the status of organ function or blood flow after

administration by increasing the relaxation rates of water protons in tissue in which the agent

accumulates [8,9]. Paramagnetic substances, superparamagnetic and ferromagnetic materials

have been used as MRI contrast agents because paramagnetic substances have a net positive

magnetic susceptibility, having the ability to become magnetized in an external magnetic

field. Some MRI exams include the use of contrast agents. The categorizations of currently

available contrast agents have been described according to their effect on the image,

magnetic behavior and biodistribution in the body, respectively [23].

Subsequently proper ligands have been designed and complexed with paramagnetic

metal ions to form strong water-soluble chelates as the first generation MRI contrast agents,

Vitamin B6 as Liver-targeting Group in Drug Delivery 155

for example, gadolinium diethylenetriaminepentaacetic acid (Gd-DTPA, Magnevist®,

Schering AG, Germany) (Figure 1) [24]. Some clinically used MRI contrast agents are small

ionic molecules such as Gd-DTPA and gadolinium 1,4,7,10-tetraazacyclododecane-N, N’,

N’’, N’’’-tetraacetic acids (Gd-DTOA, Dotarem®, Guerbet SA, France) (Figure 2) [25,26] that

can diffuse freely through the extracellular space and excreted rapidly by the kidney. Then

their biodistribution are nonspecific although Gd-DTPA works well in organs such as the

brain and spinal cord, where the normal brain parenchyma has a barrier to permeability of the

contrast agent and pathologic conditions such as cancer do not. The injection of large

quantities of the ionic complex will raise ion concentration in vivo and cause localized

disturbances in osmolality, which, in turn leads to cellular and circulatory damage. Most

commonly, Gd-DTPA and Gd-DOTA have been modified to form neutral molecules, which

thus exhibited much lower osmolality and higher LD50s in animals [27-31].

HOOCCH2

-

OOCCH2

CH2COOH

CH2COO- CH2COOGd3+

N N N

Figure 1. Structural formula of Gd-DTPA.

-

OOCCH2

-

OOCCH2 CH2COOH

CH2COOGd3+

N

N N

N

Figure 2. Structural formula of Gd-DOTA.

Nowadays ideal MRI contrast agent is focused on the neutral tissue- or organ-targeting

materials with high relaxivity and specificity, low toxicity and side effect, suitable long

intravascular duration and excretion times, high contrast enhancement with low doses in vivo,

and minimal cost of procedure [8,9,27,28]. In general, tissue or organ-specific contrast agents

consist of two components: a magnetic label capable of altering the signal intensity on MR

images and a target-group molecule having a characteristic affinity for a specific type of cell

or receptor. Some suitable residues have been incorporated into either the acetic side-arms or

the diethylenetriamine backbone of Gd-DTPA and Gd-DOTA to obtain the tissue or organspecific contrast agents. For example, liver-targeting agents such as gadobenate dimeglumine

(Gd-BOPTA, Gadobenate, Multihance®, Bracco Imaging, Italy) and gadolinium

ethoxybenzyltriamine pentaacetic acid (Gd-EOB-DTPA, Gadoxetate; Eovist®, Schering AG,

156 Guo-Ping Yan, Xiao-Yan Wang, Li-Li Mei

Germany) have been developed, which can accumulate in the liver site, increasing contrast

concentration, and producing greater signal in the MR images [32-42].

Low Molecular Weight Liver-Targeting MRI Contrast Agents

Manganese dipyridoxyl-diphosphate (mangafodipir, Mn-DPDP, Teslascan®, Nycomed

Amersham Imaging, Princeton, NJ) is a contrast agent developed for imaging of the

hepatobiliary system (Figure 3). Unlike Gd-DTPA, Mn-DPDP is an intracellular agent that is

taken up specifically by hepatocytes and pancreas, and excreted in the bile since the ligand

consists of two linked pyridoxal-5’-phosphate groups, the catalytically active form of vitamin

B6. Thus, it was thought that Mn-DPDP was a potential candidate for specific hepatocyte

uptake by the pyridoxine transporter at the sinusoidal pole. However, it was reported that the

complex dissociated both in the blood and in the liver and the uptake mechanism did not

depend on the pyridoxine transporter [4-6].

N

H3 C

-

OPOCH2

N

H+

CH2OPO -

N

H+

CH3

Mn

O

O O

O

O

O

C

C

N

OH OH

O O

Figure 3. Structural formula of Mn-DPDP.

Other liver-targeting DTPA derivates containing vitamin B6 groups have also been

prepared according to the liver-targeting property of Mn-DPDP. A series of DTPA

derivatives ligands containing pyridoxol groups have been synthesized by the reaction of

DTPA dianhydride with the pyridoxol derivatives with the different space groups. Compared

with Gd-DTPA, their non-ionic bulky Gd3+ complexes have higher relaxivities, lower

stability constants and the liver-targeting property. Moreover, Gd-DTPA and Gd-DOTA are

modified to form neutral molecules, which thus exhibit much lower osmolality, while these

neutral agents have been shown to have higher LD50s in animals [7,43,44].

Macromolecular Liver-Targeting MRI Contrast Agents

Macromolecular MRI contrast agent can be prepared by the incorporation of a low

molecular weight paramagnetic metal cheated complex such as Gd-DTDA or Gd-DOTA, to

the backbone or the pendant chains of macromolecule. It usually exhibits more effective

relaxation than that of the low molecular weight metal complex alone and improves the

Vitamin B6 as Liver-targeting Group in Drug Delivery 157

 

[66] Toole, JF; Malinow, MR; Chambless, LE; Spence, J.D.; Pettigrew, L.C.; Howard, V.J.;

Sides, E.G.; Wang, C.H.; Stampfer, M. Lowering homocysteine in patients with

ischemic stroke to prevent recurrent stroke, myocardial infarction, and death: the

Vitamin Intervention for Stroke Prevention (VISP) randomized controlled trial. JAMA,

2004; 291: 565-575

[67] Spence, J.D.; Bang, H.; Chambless, L.E.; Stampfer, M.J. Vitamin intervention for

stroke prevention trial. An efficacy analysis. Stroke, 2005; 36: 2404-2409.

[68] Bønaa K.H., Njølstad I., Ueland P.M., Schirmer H., Tverdal A., Steigen T., Nordrehaug

J.E., Arnesen E., Rasmussen K., NORVIT Trial Investigators. Homocysteine lowering

and cardiovascular events after acute myocardial infarction. N Engl J Med, 2006; 354:

1578-1588

[69] The Heart Outcomes Prevention Evaluation (HOPE) 2 Investigators. Homocysteine

lowering with folic acid and B vitamins in vascular disease. N Engl J Med, 2006; 354:

1567-1577

[70] Shemin D., Lapane K.L., Bausserman L., Kanaan E., Kahn S., Dworkin L., Bostom

A.G. Plasma total homocysteine and hemodialysis access thrombosis: a prospective

study. J Am Soc Nephrol, 1999; 10: 1095-1099.

[71] Mallamaci F., Bonanno G., Seminara G., Rapisarda F., Fatuzzo P., Candela V., Scudo

P., Spoto B., Testa A., Tripepi G., Tech S., Zoccali C. Hyperhomocysteinemia and

arteriovenous fistola thrombosis in hemodialysis patients. Am J Kidney Dis, 2005; 45:

702-707.

[72] Kim, Y.I. Nutritional epigenetics: impact of folate deficiency on DNA methylation and

colon cancer susceptibility. J Nutr, 2005; 135: 2703-2709.

[73] Kune, G.; Watson, L. Colorectal cancer protective effects and the dietary

micronutrients folate, methionine, vitamins B6, B12, C, E, selenium and lycopene. Nutr

Cancer, 2006; 56: 11-21.

[74] Zoungas S., McGrath B.P., Branley P., Kerr P.G., Muske C., Wolfe R., Atkins R.C.,

Nicholls K., Fraenkel M., Hutchison B.G., Walker R., McNeil J.J. Cardiovascular

morbidity and mortality in the Atherosclerosis and Folic Acid Supplementation Trial

(ASFAST) in chronic renal failure. JACC 2006; 47: 1108-1116.

In: Vitamin B: New Research ISBN: 978-1-60021-782-1

Editor: C. M. Elliot, pp. 139-152 © 2008 Nova Science Publishers, Inc.

Chapter VIII

VITAMIN B12, FOLATE DEPLETION AND

HOMOCYSTEINE: WHAT DO THEY MEAN

FOR COGNITION ?

Rita Moretti*

, Paola Torre and Rodolfo M. Antonello

Clinica Neurologica, Dipartimento Medicina Clinica e Neurologia,

Università degli Studi, Trieste

ABSTRACT

Vitamin B12 exerts its physiological effect on two major enzymatic pathways: the

conversion of homocysteine to methionine and the conversion of methylmalonyl

coenzyme A to succinyl coenzyme A. Disruption of either of these pathways due to

vitamin B12 deficiency results in an elevation of both serum homocysteine and

methylmalonic acid. Homocysteine levels are also elevated in the case of folate

deficiency. Serum homocysteine is proposed to be more sensitive for functional

intracellular vitamin B12 deficiency than analysis of vitamin B12 in serum. Hence,

homocysteine, vitamin B12, and folate are closely linked together in the so-called onecarbon cycle. The proposed mechanism relates to the methylation reactions involving

homocysteine metabolism in the nervous system. Vitamin B12 is the necessary coenzyme, adequate for the correct functioning of the methyl donation from 5

Methyltethrahydrofolate in tetrhahydrofolate, necessary for methionine synthetase. On

the other hand, folate is a cofactor in one-carbon metabolism, during which it promotes

the remethylation of homocysteine- a cytotoxic sulfur-containing amino acid that can

induce DNA strand breakage, oxidative stress and apoptosis. What clearly merges from

Literature is the general conviction that vitamin B12 and folate, directly through the

maintenance of two functions, nucleic acid synthesis and the methylation reactions, or

indirectly, due to their lack which cause SAM mediated methylation reactions inhibition

*

 Corresponding Author: Rita Moretti, MD, Clinica Neurologica dell’Università degli Studi di Trieste, Ospedale di

Cattinara, Strada di Fiume, 447, 34149 TRIESTE, Italy; phone:0039-40-3994321; FAX: 0039-40-910861; email: moretti@univ.trieste.it

140 Rita Moretti, Paola Torre and Rodolfo M. Antonello

by its product SAH, and through the related toxic effects of homcystein which cause

direct damage to the vascular endothelium and inhibition of N-methyl-D-Aspartate

receptors, can cause neuropsychiatric disturbances.

INTRODUCTION

It is today well known that vitamin B12 deficiency can be associated with

neuropsychiatric symptoms. Several studies have previously demonstrated that vitamin B12

deficiency is more common in patients with dementia symptoms than in the cognitively nonimpaired. Vitamin B12 deficiency increases with age and is present in 5-40% of the elderly

population. However, the mechanism of neurological damage induced by a quantitative or

functional vitamin B12 deficiency is still unclear.

Vitamin B12 exerts its physiological effect on two major enzymatic pathways: the

conversion of homocysteine to methionine and the conversion of methylmalonyl coenzyme A

to succinyl coenzyme A. Disruption of either of these pathways due to vitamin B12

deficiency results in an elevation of both serum homocysteine and methylmalonic acid.

Homocysteine levels are also elevated in the case of folate deficiency. Serum homocysteine is

proposed to be more sensitive for functional intracellular vitamin B12 deficiency than

analysis of vitamin B12 in serum. Hence, homocysteine, vitamin B12, and folate are closely

linked together in the so-called one-carbon cycle. The proposed mechanism relates to the

methylation reactions involving homocysteine metabolism in the nervous system. It has been

suggested that the brain suffers from a double whammy from hyperhomocysteinaemia:

cerebrovascular damage that triggers or potentiates the effect of Alzheimer pathology

combined with a direct neurotoxic effect of homocysteine [1].

Low levels of vitamin B12 and that of low levels of serum folate still raise debates on

their possible role in cognition. The practice parameter for the diagnosis of dementia

concluded with different recommendations, based on the evidence in the literature. Among

them, screening for depression, B12 deficiency and hypothyroidism should be performed [2,

3,4, 5, 6, 7].

Albeit the theoretical importance of the determination of folate and vitamin B12 blood

levels, there is a general confusion on their possible role in neuropsychiatric alterations.

BYOCHEMISTRY OF FOLATE, VITAMIN B12,

AND HOMCYSTEINE

Congenital B vitamins that participate in one-carbon metabolism (ie folate, vitamin B12,

and vitamin B6) deficiency is associated with severe impairment of brain function [8, 9, 10,

11].

Folate and vitamin B12 are required both in the methylation process. The de novo

synthesis of methionine requires vitamin B12, which is involved directly in the transfer of the

methyl group to homocysteine. In turn, methionine is required in the synthesis of S-

Vitamin B12, Folate Depletion and Homcysteine… 141

adenosylmethionine (SAM) the sole donor in numerous methylation reactions involving

proteins, phospholipids and biogenic amines (figure 1).

Figure 1. Chemical structure of vitamin B12.

The pathway of one-carbon metabolism is characterized by the generation of one-carbon

units, normally from serine, made active through association with tetrahydrofolate (figure 2).

The resulting 5,10-methylentetrahydrofolate is subsequently used for the synthesis of

thymidylate and purines (used for nucleic acid synthesis) and of methionine, which is used

for protein synthesis and biological methylations. The methionine synthesis is preceded by

the irreversible reduction of 5,10 methylentetrahydrofolate to 5-methyltetrahydrofolate in a

142 Rita Moretti, Paola Torre and Rodolfo M. Antonello

reaction that is catalysed by the flavin-containing methylentetrahydrofolate reducatase.

Subsequently, 5-methyltetrahydrofolate serves a substrate to methylate homocysteine in a

reaction that is catalysed by a vitamin B12 containing methyltransferase.

Figure 2. Folate Acid: chemical structure.

Figure 3. Synthesis of SAM for the DNA methylation.

Homocysteine is also methylated by betaine in a reaction not involving vitamin B12. A

considerable proportion of methionine is activated by ATP to form S-adenosylmethionine

(SAM) [12] which serves primarily as a universal methyl donor in a variety of reactions. In

the brain, SAM-dependent methylations are extensive and the products of these reactions

Vitamin B12, Folate Depletion and Homcysteine… 143

include neurotransmitters such as catecholamines and indoleamines, phospholipids and

myelins. Upon transfer of its methyl group, SAM is converted to S-adenosylhomocysteine

(SAH), rapidly and subsequently hydrolysed to homocysteine and adenosine [13] (See figure

3).

This hydrolysis is a reversible reaction that favours SAH synthesis. Thus, in the state of

folate or vitamin B12 deficiency, the sequential inability to methylate homocysteine leads to

SAH intracellular accumulation. If homcysteine is allowed to accumulate, it will be rapidly

metabolised to SAH, which is a strong inhibitor of all methylation reaction, competing with

SAM for the active site on the methyltransferase enzyme protein [14; 15; 16; 17].

It has been hypothesized that a pathway of oxidation of homocystein to homocysteic acid

is the potential explanation of the dangerous effect of homocysteine. In fact, homocysteic

acid is a mixed excitatory agonist preferentially at NMDA receptors [18].

Elevated levels of homocysteine in the blood predispose to arteriosclerosis [19, 20]: as

many as 47% of patients with arterial occlusions manifest modest elevations in plasma

homocysteine [20]. The strength of the association between homocysteine and

cerebrovascular disease appears to be greater than that between homocysteine and coronary

heart disease or peripheral vascular disease. Moreover, homocysteine is also an agonist at the

glutamate site of the NMDA receptor and is therefore a potential excitotoxin. Elevated

glycine levels synergize with homocysteine to overstimulate NMDA receptors and contribute

to neuronal damage. Indeed, the toxicity of cysteine may derive in part from reaction with

bicarbonate and in part from the disulfide cysteine, which is transported into neurons in

exchange for the extracellular transport of glutamate via the anionic cystine glutamate

transporter. In the latter case, the local rise in extracellular excitatory amino acids could then

contribute to neurotoxicity [19].

WHAT HAPPENS IF VITAMIN B12 OR FOLATE

LEVELS ARE UNDER NORMAL RANGE?

Vitamin B12 is the necessary co-enzyme, adequate for the correct functioning of the

methyl donation from 5 Methyltethrahydrofolate in tetrhahydrofolate, necessary for

methionine synthetase. On the other hand, folate is a cofactor in one-carbon metabolism,

during which it promotes the remethylation of homocysteine- a cytotoxic sulfur-containing

amino acid that can induce DNA strand breakage, oxidative stress and apoptosis.

The biochemical basis of the interrelationship between folate and cobalamin is the

maintenance of two functions, nucleic acid synthesis and the methylation reactions. The latter

is particularly important in the brain and relies especially on maintaining the concentration of

S-adenosylmethionine (SAM). SAM mediated methylation reactions are inhibited by its

product S-adneosylhomocysteine (SAH). This occurs when cobalamin is deficient and, as a

result, methionine synthase is inhibited causing a rise of both homcysteine and SAH. Other

potential pathogenic processes related to the toxic effects of homcystein are direct damage to

the vascular endothelium and inhibition of N-methyl-D-Aspartate receptors [21, 22, 23, 24,

25, 26, 27, 28, 29, 30].

144 Rita Moretti, Paola Torre and Rodolfo M. Antonello

CLINICAL IMPLICATIONS

Data obtained from Literature stand that vitamin B12 is somehow bound to cognition and

to the implementation of active strategies to coordinate and well do in active problem

solving.

There are different causes which can produce cobalamin deficiency: an inadequate

intake, malabsorption, drugs, genetic deficiency of transcobalamin II. However, Larner et al.

[31; 32] reported that the effective number of vitamin B12 defect-dementia is extremely

small. Though, elderly individuals with cobalamin deficiency may present with

neuropsychatric or metabolic deficiencies, without frank macrocytic anemia [33, 34].

Psychiatric symptoms attributable to vitamin B12 deficiency have been described for

decades. These symptoms seem to fall into several clinically separate categories: slow

cerebration, confusion, memory changes, delirium with or without hallucinations and or

delusions, depression, acute psychotic states, and more rarely reversible manic and

schizophreniform states. Moreover, acute or subacute changes in a demented patient’s mental

status, specifically a clouding of their consciousness, may be due to a lack of vitamin B12

[35].

A higher prevalence of lower serum vitamin B12 levels have been found in subjects with

AD [36], other dementias [37] and in people with different cognitive impairments [31; 38], as

compared with controls. In contrast, other cross-sectional studies [39; 40] have failed to find

this association. The most recent study [41] on the topic examined the relationship between

vitamin B12 serum levels and cognitive and neuropsyhciatric symptoms in dementia. In AD,

the prevalence of low vitamin B12 serum levels is consistent with that found in community

dwelling elderly persons in general but is associated with greater overall cognitive

impairment.

Furthermore, some intervention studies have shown the effectiveness of vitamin B12

supplementation in improving cognition in demented or cognitively impaired subjects.

Chronic dementia responds poorly but should nevertheless be treated if there is a metabolic

deficiency (as indicated by elevated homocysteine and/or methylmalonic acid levels) [34].

These data have been confirmed by other studies [42; 43; 44 ; 45]. The B12 supplemented

patients who presented with dementia showed no significant improvement, and no less

deterioration, in their neuropsychological function than their matched group. However, a

treatment effect was demonstrated among the patients presenting with cognitive impairment.

These improved significantly compared to matched patients on the verbal fluency test. The

conclusion could be that vitamin B12 treatment may improve frontal lobe and language

function in patients with cognitive impairment, but rarely reverses dementia.

On the contrary, other works have failed to confirm the optimistic results [46, 47].

Cobalamin supplementation was given to al patients and the effect was evaluated after 6

months. When the size and the pattern of individual change scores, and the mean change

scores on all instruments were taken into account, functioning after replacement therapy was

not improved. When change scores of treated patients were compared with those of patients

with AD, vitamin B12 replacement did not result in slowing of the progression of dementia.

Many Different studies have tried to describe a possible consequence of the combined defect

of vitamin B12 and folate. Lower folate and vitamin B12 concentrations were associated with

Vitamin B12, Folate Depletion and Homcysteine… 145

poorer spatial copying skills. In addition, plasma homocysteine concentration, which is

inversely correlated with plasma folate and vitamin B12 concentrations, was a stronger

positive predictor of spatial copying performance than either folate or vitamin B12

concentrations: effective role in a clinical population is at the moment quite controversial [48,

49, 50, 51, 52, 53, 54, 55].

Recent epidemiological and experimental studies have linked folate deficiency and

resultant increased homocystein levels with several neurodegenerative conditions, including

stroke, AD, and Parkinson’s disease [56, 57, 58]. Folate deficiency sensitises mice to

dopaminergic neurodegeneration and motor dysfunction caused by neurotoxin MPTP.

Additional experiments indicate that this effect of folate deficiency may be mediated (again!)

by homocysiteine. These findings suggest that folate deficiency and hyperhomocysteinemia

are risk factors for Parkinsons’s disease.

One of the most recent review on folic acid [56] clearly states its importance in

neuropsychiatric disorders. Depression is commoner in patients with folate deficiency, and

subacute combined degeneration with peripheral neuropathy is more frequent in those with

vitamin B12 deficiency [59, 60, 61, 62, 63]. A close association with dementia and

depression, apathy, withdrawal, and lack of motivation has been noted [64]. One reason far

the apparently high incidence of folate deficiency in elderly people is that folate

concentrations in serum and cerebrospinal fluid fall and plasma homocysteine rises with age,

perhaps contributing to the ageing process [65, 66]. Considering that recent epidemiologic

studies [67; 68; 69; 70; 71] have shown an association between low serum folate levels and

risk of vascular disease, including stroke and various types of vascular cognitive impairment,

this work [66] examined data from the Canadian Study of Health and Ageing. The risk

estimate for an adverse cerebrovascular event associated with the lowest folate quartile

compared with the highest quartile was OR 2.42 (95%CI; 1.04-5.61). Results from stratified

analyses also showed that relatively low serum folate was associated with a significantly

higher risk of an adverse cerebrovascular event among female (OR 4.02, 95%CI; 1.37-11.81)

subjects [72, 73, 74, 75, 76].

Recently, the much larger and longer Framingham community based study confìrmed

that a raised plasma homocysteine (bound to folate level) concentration doubled the risk of

developing Alzheimer's and non-Alzheimer's dementia [77, 78]. In a relatively small sample

[79], serum folate had a strong negative association with the severity of atrophy of the

neocortex, and none of the other nutritional markers examined had significant associations

with atrophy in this study. Folate was related to atophy only among participants with a

significant number of Alzheimer disease lesions in the neocortex. This finding suggests that

folate may exacerbate the likelihood of atrophy only when an atrophying disease process

such as Alzheimer disease is present (with a positive relationship between low level of folate

and an impairment of memory, 80). In other case-control studies in patients with Alzheimer's

disease, cognitive decline was significantly associated with raised plasma homocysteine and

lowered serum folate (and vitamin B12) concentration [81, 82, 83].

146 Rita Moretti, Paola Torre and Rodolfo M. Antonello

HOW LABORATORY HELPS THE CLINICIAN?

Two new markers, plasma homocysteine and serum methylmalonic acid reflect the

functional status of cobalamins and folates in the tissues [84]. Since elevated homocysteine

levels can often be normalized by supplementing the diet with folic acid, pyridoxine

hydrochloride and cyanocobalamin, these observations raise the exciting possibility that this

inexpensive and well-tolerated therapy my be effective in decreasing the incidence of

vascular disease [85]. In addition to its association with cerebrovascular disease,

homocysteine may play a role in neurodegenerative disorders, even if only as a marker of

functional vitamin B12 deficiency.

A recent study [86] showed that B vitamins and homocysteine have been associated with

cognitive variation in old age. Serum total homcysteine levels were significantly higher and

serum folate and vitamin B12 levels were lower in patients with dementia of AD type and

with histologically confirmed AD than in controls [81]. After 3 years of follow-up, there was

significantly greater radiological evidence of disease progression assessed by medial

temporal lobe thickness, among those with total homocysteine levels in the middle and upper

compared with those in the lower tertile, who showed little atrophy [81]. The stability of total

homocysteine levels over time and lack of relationship with duration of symptoms argue

against these findings being a consequence of disease and warrant further studies to assess

the clinical relevance of these associations for AD [81].

Homocysteine has a direct consequence for neurotoxic effects on hippocampal and

cortical neurons [88, 89]. The findings of the study suggest that higher homocysteine levels

may be associated with early Alzheimer pathology.

On the other hand, hyperhomocysteinemia is a strong risk factor for atherosclerotic

vascular disease. In different recent study [90, 91], significantly elevated homocysteine levels

were found in patients with AD as well as in patients with vascular dementia, probably

indicating similar pathophysiological pathways. Prospective double-blind and placebocontrolled intervention studies are not available. If homocysteine-lowering therapy will be in

the running for the prevention and treatment of dementia, the clinician, at the moment, must

be able to diagnose the disease at a preclinical stage (5 to 10 years before the disease

becomes clinically overt for AD).

This might be a key point in the clinical practice in order to define dementia, either the

degenerative either the vascular form, as a complex relationship between oxidative,

inflammatory and degeneration. The last one, probably, might not have the primary role, as it

has, if the first two steps do not occur.

What clearly merges from Literature is the general conviction that vitamin B12 and

folate, directly through the maintenance of two functions, nucleic acid synthesis and the

methylation reactions, or indirectly, due to their lack which cause SAM mediated methylation

reactions inhibition by its product SAH, and through the related toxic effects of homcystein

which cause direct damage to the vascular endothelium and inhibition of N-methyl-DAspartate receptors, can cause neuropsychiatric disturbances.

Vitamin B12, Folate Depletion and Homcysteine… 147

REFERENCES

[1] Nagga K. Invited Comments. Neurol. India. 2005;53:59-59

[2] Knopman D., Cummings JL., DeKosky S, Chui H, Corey-Bloom J, Relkin N, Small G,

Miller C, Stevens J. Practice parameter: diagnosis of dementia. American Academy of

Neurology, Philadelphia, 2001; 2FC.005-16-36.

[3] Clarfield AM. The reversible dementias: do they reverse? Ann. Intern. Medicine, 1988,

109: 476-486.

[4] White L, Petrovich H, Ross GW, et al. Prevalence of dementia in older JapaneseAmerican men in Hawaii: the Honolulu-Asia Aging Study. JAMA, 1996; 276: 955-960.

[5] Weytingh MD, Bossuyt PM, van Crevel H. Reversible dementia: more than 10% or less

than 1%? A quantitative review. J. Neurology, 1995; 242: 466-471.

[6] Knopman DS, DeKosky ST, Cummings JL, Chui H, Corey-Bloom J, Relkin N, Small

GW, Miller B, Stevens JC. Practice parameter: diagnosis of dementia (an evidencebased review). Report of the Quality Standards Subcommittee of the American

Academy of Neurology. Neurology, 2001; 56: 1143-1153.

[7] Petersen RC, Corey-Bloom J. Differential diagnosis of dementia: improvements in

detection techniques. American Academy of Neurology, 2003 Honolulu: 7BS.004-21;

31-65.

[8] Selhub J, Bagley LC, Mille J, Rosenberg IH. B vitamins, homocysteine, and

neurocognitive function in the elderly. Am. J. Clin. Nutr. 2000 ; 71(2): S614-S620.

[9] Nilsson-Ehle H. Age-related changes in cobalamin (vitamin B12) handling. Implication

for therapy. Drug Aging. 1998; 12: 277-292.

[10] Bottiglieri T. Folate and vitamin B12 and neuropsychiatric disorders. Nutrition

Reviews. 1996, 54 (12), 133-151.

[11] Wang HX, Wahlin A, Basun H, Fastbom J, Winblad B, Fratiglioni L. Vitamin B12 and

folate in relation to the development of Alzheimer’s disease. Neurology, 2001; 56:

1188-1194.

[12] Lindenbaum J, Rosenberg IH, Wilson PWF, et al. Prevalence of vitamin B12

deficiency among geriatric outpatients. J. Fam. Pract. 1992; 35: 524-528.

[13] Parnetti L, Bottiglieri T, Lowenthal D. Role of homocysteine in age-related vascular

and non-vascular disease. Aging. 1997; 9: 241-257.

[14] Enk D,Hougarad K, Hippe E. Reversible dementia and neuropathy associated with

folate deficiency 16 years after partial gastrectoy. Scand J. Hematol. 1980; 25: 63-66.

[15] Bottiglieri T. S-Adenomethinone (SAM) neuropharmachology: implications for

pharmachological therapy of psychiatric and neurological diseases. Exp. Opin. Invest.

Drugs, 1997, 6 (4): 417-426.

[16] Weir Dg., Keating S., Malloy A. methylation deficiency causes vitamin-b12 associated

neuropathy in the pig. J. Neurochem. 1988, 51: 1949-1952.

[17] Surtees R., Leonard J., Austin S. Association of demyelination with deficiency of

cerebrospinal fluid S-adenosylmethionine in inborn errors of methyltransferase

pathway. Lancet, 1991, 338: 1550-1554.

[18] Shaw PJ. Excitatory amino acid receptors, excitotoxicity and the human nervous

system. Curr. Opin. Neurol. Neurosurg. 1993; 6: 414-418.